Norway· NO-ID_37272FD1-E380-4C3E-AA22-5C734B081C0C
Saphnelo
A anifrolumab product containing anifrolumab, registered in Norway by AstraZeneca AB (2). The same ATC class is registered in 12 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Anifrolumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG11 (anifrolumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Anifrolumab · ATC L04AG11
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of anifrolumab costs, country by country.
Normalised to the WHO defined daily dose (10.7 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Anifrolumab · price per daily dose (10.7 mg)
USD · FX 28 Sept 2026
- CH Switzerland$42.60
The record
At a glance
FEST (Norway)- Active substance
- Anifrolumab
- Manufacturer
- AstraZeneca AB (2)
- Country
- Norway (NO)
- ATC code
- L04AG11
- ATC class
- Anifrolumab
- Defined daily dose
- 10.7 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_37272FD1-E380-4C3E-AA22-5C734B081C0C
- no_varenummer4690032NOK 12338.8
- gtin5000456070645
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Anifrolumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumSaphnelo 300 mgAstraZeneca
- CzechiaSAPHNELOAstraZeneca AB, Södertälje
- FinlandSaphneloAstraZeneca AB
- IrelandSaphnelo 300 mg Concentrate for solution for infusionAstraZeneca AB
- IcelandSaphneloAstraZeneca AB*
- PolandSaphneloAstraZeneca AB
- SwedenSAPHNELO 300 mg Koncentrat till infusionsvätska, lösningAstraZeneca AB
- SwitzerlandSaphnelo 120 mg/0.8 ml, Injektionslösung in einem FertigpenAstraZeneca AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Saphnelo
- Liechtenstein · Saphnelo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/83f1f5f6-33af-4c2f-a414-e8bd60bbd282 GET /v1/drugs/83f1f5f6-33af-4c2f-a414-e8bd60bbd282?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Anifrolumab",
"merkevare_id": "ID_37272FD1-E380-4C3E-AA22-5C734B081C0C",
"name_form_strength": "Saphnelo kons til inf oppl 300 mg",
"prescription_group": "C"
}See everything about anifrolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.